Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999;5:178 87. 180. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dini- trate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049 57. 181. Pitt B, Zannad F, Remme WJ, et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709 17. 182. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364: 11 21. 183. Packer M, Poole-Wilson PA, Armstrong PW, et al., ATLAS Study Group. Comparative effects of low and high doses of the angiotensin- converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312 8. 184. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309 21. 185. CBIS II Authors. The Cardiac Insuf ciency Bisoprolol Study II (CIBIS- II): a randomised trial. Lancet 1999;353:9 13. 186. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651 8. 187. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT- HF). Lancet 1999;353:2001 7. 188. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547 52. 189. Granger CB, McMurray JJ, Yusuf S, et al. 